Patients and physicians must be able to trust that the medicine in the bottle is the same as that which is described in the label. Pfizer wants to ensure that patients do not receive generic products that fail to meet FDA standards. |
Patients and physicians must be able to trust that the medicine in the bottle is the same as that which is described in the label. We want to ensure that patients do not receive generic products that fail to meet FDA standards. |
Quite frankly, with the two companies together we can get more out of the pipeline than we could separately. |
Revenues in the third quarter of 2005 reflected lower prescription growth and increased competition in key therapeutic markets in the U.S., such as the lipid-lowering market, where the rate of growth in the third quarter declined significantly versus the first half of the year; and the erectile dysfunction market, which has been in decline compared to 2004. |
The fact that half of our companies are planning to increase spending on plants, equipment and technology bodes well for economic growth. |
There has to be a balanced approach, which first satisfies our need for security and at the same time makes sure we allow reasonable access to foreign investors to the United States. |
These clinical trial results are new, |
They had been putting the same percentage increase on each quarter, and in an unusually low quarter like last year that didn't' work, ... So we directed them to take down their second-quarter estimates through our guidance. |
This court decision is consistent with the fundamental principle that patent laws exist to support and encourage medical innovators, not undermine them, |
This is a healthy rate of growth. So 3.3 percent into 2006 ... represents a continuing strong economy. |
This is a normal part of our planning cycle, |
This is a normal part of our planning cycle, ... You should have as much confidence in us this week as you had last week. |
This is a time of transformation for Pfizer and our industry. We are responding directly to the realities of our operating environment as we build value today while aggressively investing in the future. |
This was a huge win for Pfizer. |
We are evaluating our financial prospects for 2006 and 2007 in light of current and anticipated business conditions and are withdrawing our prior guidance for those years, |